Anti-tumor immunotherapy research currently is focused on a static time point or solo pathway of the tumor microenvironment (TME), contrary to this, these scientists investigated the effect of cross-talk and dynamic expression of the TIGIT/CD96, PD-L1/PD-1, CD155/CD96, CD155/DNAM-1 axes on the anti-tumor function of CD8+ T cells in the TNBC TME. The gene discussed is PVR; the disease is neoplasm.